Clinical Lung Cancer

1

Preclinical Efficacy of Vascular Disrupting Agents in Non–Small-Cell Lung Cancer

Bruce C. Baguley

Journal:

Year:

2011

Language:

english

File:

PDF, 645 KB

english, 2011

2

Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010): Focus on Developmental Therapeutics Related to Lung Cancer

Daniel Morgensztern, Nathan A. Pennell, Janakiraman Subramanian, Ramaswamy Govindan

Journal:

Clinical Lung Cancer

Year:

2011

Language:

english

File:

PDF, 238 KB

english, 2011

3

Second-line Paclitaxel/Carboplatin Versus Vinorelbine/Carboplatin in Patients Who Have Advanced Non–Small-Cell Lung Cancer Pretreated With Non–Platinum-Based Chemotherapy: A Multicenter Randomized Phase II Study

Athanasios G. Pallis, Kostas Syrigos, Athanasios Kotsakis, Niki Karachaliou, Aris Polyzos, Vassilis Chandrinos, Ioannis Varthalitis, Charalambos Christophyllakis, Alexandros Ardavanis, Lambros Vamvaka

Journal:

Clinical Lung Cancer

Year:

2011

Language:

english

File:

PDF, 361 KB

english, 2011

4

Prognostic Impact of Angiogenic Markers in Non–Small-Cell Lung Cancer is Related to Tumor Size

Tom Donnem, Sigve Andersen, Samer Al-Saad, Khalid Al-Shibli, Lill-Tove Busund, Roy M. Bremnes

Journal:

Clinical Lung Cancer

Year:

2011

Language:

english

File:

PDF, 1.45 MB

english, 2011

5

First- or Second-line Gefitinib Therapy in Unknown Epidermal Growth Factor Receptor Mutants of Non–Small-Cell Lung Cancer Patients Treated in Taiwan

Chien-Hao Lie, Huang-Chih Chang, Tung-Ying Chao, Yu-Hsiu Chung, Jui-Long Wang, Chin-Chou Wang, Meng-Chih Lin

Journal:

Clinical Lung Cancer

Year:

2011

Language:

english

File:

PDF, 1.14 MB

english, 2011

6

Phase I/II Trial of a COX-2 Inhibitor With Limited Field Radiation for Intermediate Prognosis Patients Who Have Locally Advanced Non–Small-Cell Lung Cancer: Radiation Therapy Oncology Group 0213

Elizabeth Gore, Kyounghwa Bae, Corey Langer, Martine Extermann, Benjamin Movsas, Paul Okunieff, Gregory Videtic, Hak Choy

Journal:

Clinical Lung Cancer

Year:

2011

Language:

english

File:

PDF, 247 KB

english, 2011

7

Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Non–Small-Cell Lung Cancer With the Absence of Epidermal Growth Factor Receptor Mutations

Gabriella Farina, Flavia Longo, Olga Martelli, Ida Pavese, Andrea Mancuso, Luca Moscetti, Roberto Labianca, Alessandro Bertolini, Enrico Cortesi, Antonio Farris, Daniele Fagnani, Maria Cristina Locate

Journal:

Clinical Lung Cancer

Year:

2011

Language:

english

File:

PDF, 524 KB

english, 2011

8

Baseline Levels and Decrease in Serum Soluble Intercellular Adhesion Molecule-1 During Chemotherapy Predict Objective Response and Survival in Patients Who Have Advanced Non–Small-Cell Lung Cancer

Qian Qian, Ping Zhan, Like Yu, Yi Shi, Jinfei Cheng, Shuzhen Wei, Qian Wang, Yong Song

Journal:

Clinical Lung Cancer

Year:

2011

Language:

english

File:

PDF, 766 KB

english, 2011

9

Editorial Board

Journal:

Clinical Lung Cancer

Year:

2011

Language:

english

File:

PDF, 62 KB

english, 2011

10

History of Small-Cell Lung Cancer

Shadi Haddadin, Michael C. Perry

Journal:

Clinical Lung Cancer

Year:

2011

Language:

english

File:

PDF, 269 KB

english, 2011

Volume 12; Issue 2

Preclinical Efficacy of Vascular Disrupting Agents in Non–Small-Cell Lung Cancer

Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010): Focus on Developmental Therapeutics Related to Lung Cancer

Second-line Paclitaxel/Carboplatin Versus Vinorelbine/Carboplatin in Patients Who Have Advanced Non–Small-Cell Lung Cancer Pretreated With Non–Platinum-Based Chemotherapy: A Multicenter Randomized Phase II Study

Prognostic Impact of Angiogenic Markers in Non–Small-Cell Lung Cancer is Related to Tumor Size

First- or Second-line Gefitinib Therapy in Unknown Epidermal Growth Factor Receptor Mutants of Non–Small-Cell Lung Cancer Patients Treated in Taiwan

Phase I/II Trial of a COX-2 Inhibitor With Limited Field Radiation for Intermediate Prognosis Patients Who Have Locally Advanced Non–Small-Cell Lung Cancer: Radiation Therapy Oncology Group 0213

Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Non–Small-Cell Lung Cancer With the Absence of Epidermal Growth Factor Receptor Mutations

Baseline Levels and Decrease in Serum Soluble Intercellular Adhesion Molecule-1 During Chemotherapy Predict Objective Response and Survival in Patients Who Have Advanced Non–Small-Cell Lung Cancer

Editorial Board

Table of Contents

History of Small-Cell Lung Cancer